Guy Lambrecht

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

Geert D’Haens, Filip Baert, Gert Van Assche et al. · The Lancet · 2008 · 1.2K citations

Medicine, Clinical Sciences, Immunology +12

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

Geert D’Haens, Séverine Vermeire, Guy Lambrecht et al. · Gastroenterology · 2018 · 299 citations · Full text

Veterinary Medicine, Clinical Sciences, Pharmacotherapy +12

Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy

Martine De Vos, Édouard Louis, Jørgen Jahnsen et al. · Inflammatory Bowel Diseases · 2013 · 204 citations

Medicine, Clinical Sciences, Internal Medicine +14

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Édouard Louis, Matthieu Resche‐Rigon, David Laharie et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 108 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease

Erwin Dreesen, Filip Baert, David Laharie et al. · Clinical Gastroenterology and Hepatology · 2019 · 85 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16